利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.019 秒)

    IDENTIFICATION OF MULTI-MODAL ASSOCIATIONS BETWEEN BIOMEDICAL MARKERS
    2.
    发明申请
    IDENTIFICATION OF MULTI-MODAL ASSOCIATIONS BETWEEN BIOMEDICAL MARKERS 审中-公开
    鉴定生物医学标记之间的多模式协会

    公开(公告)号：US20130196877A1

    公开(公告)日：2013-08-01

    申请号：US13877346

    申请日：2011-10-04

    申请人： Nilanjana Banerjee ,  Angel Janevski ,  Sitharthan Kamalakaran ,  Vinay Varadan ,  Nevenka Dimitrova ,  Robert Lucito

    发明人： Nilanjana Banerjee ,  Angel Janevski ,  Sitharthan Kamalakaran ,  Vinay Varadan ,  Nevenka Dimitrova ,  Robert Lucito

    IPC分类号： G06F19/20

    CPC分类号： G16B25/00 ,  G16B5/00 ,  G16B20/00

    摘要： The present invention relates to a method for identifying multi-modal associations between biomedical markers which allows for the determination of network nodes and/or high ranking network members or combinations thereof, indicative of having a diagnostic, prognostic or predictive value for a medical condition, in particular ovarian cancer. The present invention further relates to a biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy, preferably a platinum based cancer therapy, wherein said bio-medical marker or group of biomedical markers comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 8, 19, 20 or all markers selected from PKMYT1, SKIL, RAB8A, HIRIP3, CTNNB1, NGFR, ZCCHC11, LSP1, CD200, PAX8, CYBRD1, HOXC11, TCEAL1, FZD10,FZD1, BBS4, IRS2, TLX3, TSPAN2, TXN, and CFLAR. Furthermore, an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, 1 diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular ovarian cancer, is provided, as well as a corresponding method for classifying a subject comprising and a medical decision support system.

    摘要翻译： 本发明涉及一种用于识别生物医学标记之间的多模式关联的方法，其允许确定网络节点和/或高排名网络成员或其组合，指示具有用于医疗状况的诊断，预后或预测值， 特别是卵巢癌。 本发明还涉及与受试者对癌症治疗（优选基于铂的癌症治疗）的高反应性的高可能性相关联的生物医学标记物或生物医学标记物组，其中所述生物医学标记物或生物医学标记物组至少包括 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,8,19,20或选自PKMYT1，SKIL，RAB8A， HIRIP3，CTNNB1，NGFR，ZCCHC11，LSP1，CD200，PAX8，CYBRD1，HOXC11，TCEAL1，FZD10，FZD1，BBS4，IRS2，TLX3，TSPAN2，TXN和CFLAR。 此外，提供了用于检测，诊断，毕业，监测或预测医学状况或用于检测1诊断，监测或预测受试者对于针对所述医学病症，特别是卵巢癌的治疗的反应性的测定法，作为 以及用于分类受试者的相应方法以及医疗决策支持系统。

    Identification of multi-modal associations between biomedical markers
    3.
    发明授权
    Identification of multi-modal associations between biomedical markers 有权

    公开(公告)号：US10340027B2

    公开(公告)日：2019-07-02

    申请号：US13877346

    申请日：2011-10-04

    申请人： Nilanjana Banerjee ,  Angel Janevski ,  Sitharthan Kamalakaran ,  Vinay Varadan ,  Nevenka Dimitrova ,  Robert Lucito

    发明人： Nilanjana Banerjee ,  Angel Janevski ,  Sitharthan Kamalakaran ,  Vinay Varadan ,  Nevenka Dimitrova ,  Robert Lucito

    IPC分类号： G01N33/48 ,  G16B25/00 ,  G16B5/00 ,  G06G7/58 ,  G16B20/00

    摘要： The present invention relates to a method for identifying multi-modal associations between biomedical markers which allows for the determination of network nodes and/or high ranking network members or combinations thereof, indicative of having a diagnostic, prognostic or predictive value for a medical condition, in particular ovarian cancer. The present invention further relates to a biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy, preferably a platinum based cancer therapy, wherein said biomedical marker or group of biomedical markers comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 8, 19, 20 or all markers selected from PKMYT1, SKIL, RAB8A, HIRIP3, CTNNB1, NGFR, ZCCHC11, LSP1, CD200, PAX8, CYBRD1, HOXC11, TCEAL1, FZD10, FZD1, BBS4, IRS2, TLX3, TSPAN2, TXN, and CFLAR. Furthermore, an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, 1 diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular ovarian cancer, is provided, as well as a corresponding method for classifying a subject comprising and a medical decision support system.

    METHOD FOR ESTIMATION OF INFORMATION FLOW IN BIOLOGICAL NETWORKS
    5.
    发明申请
    METHOD FOR ESTIMATION OF INFORMATION FLOW IN BIOLOGICAL NETWORKS 审中-公开
    生物网络信息流估计方法

    公开(公告)号：US20140040264A1

    公开(公告)日：2014-02-06

    申请号：US13983651

    申请日：2012-01-30

    申请人： Vinay Varadan ,  Prateek Mittal ,  Sitharthan Kamalakaran ,  Nevenka Dimitrova ,  Angel Janevski ,  Nilanjana Banerjee

    发明人： Vinay Varadan ,  Prateek Mittal ,  Sitharthan Kamalakaran ,  Nevenka Dimitrova ,  Angel Janevski ,  Nilanjana Banerjee

    IPC分类号： G06F19/00

    CPC分类号： G06F19/324 ,  G16B5/00 ,  G16B25/00 ,  G16B40/00

    摘要： The present invention relates to a method for stratifying a patient into a clinically relevant group comprising the identification of the probability of an alteration within one or more sets of molecular data from a patient sample in comparison to a database of molecular data of known phenotypes, the inference of the activity of a biological network on the basis of the probabilities, the identification of a network information flow probability for the patient via the probability of interactions in the network, the creation of multiple instances of network information flow for the patient sample and the calculation of the distance of the patient from other subjects in a patient database using multiple instances of the network information flow. The invention further relates to a biomedical marker or group of biomedical markers associated with a high likelihood of responsiveness of a subject to a cancer therapy wherein the biomedical marker or group of biomedical markers comprises altered biological pathway markers, as well as to an assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular ovarian cancer. Furthermore, a corresponding clinical decision support system is provided.

    摘要翻译： 本发明涉及一种用于将患者分层为临床相关组的方法，其包括鉴定来自患者样品的一组或多组分子数据内的改变概率与已知表型的分子数据的数据库相比较， 基于概率推断生物网络的活动，通过网络中的交互概率识别患者的网络信息流概率，创建患者样本的多个网络信息流实例和 使用网络信息流的多个实例来计算患者与患者数据库中的其他受试者的距离。 本发明进一步涉及生物医学标记物或生物医学标记物组，其与受试者对癌症治疗的响应性的高可能性相关联，其中生物医学标记物或生物医学标记物组包括改变的生物学途径标志物，以及用于检测 ，诊断，毕业，监测或预测医学状况，或用于检测，诊断，监测或预测受试者对于针对所述医学病症，特别是卵巢癌的治疗的反应性。 此外，提供了相应的临床决策支持系统。

    INTEGRATED ACCESS TO AND INTERATION WITH MULTIPLICITY OF CLINICA DATA ANALYTIC MODULES
    7.
    发明申请
    INTEGRATED ACCESS TO AND INTERATION WITH MULTIPLICITY OF CLINICA DATA ANALYTIC MODULES 审中-公开
    综合访问和与临床数据分析模块的多重性相关联

    公开(公告)号：US20130282404A1

    公开(公告)日：2013-10-24

    申请号：US13976170

    申请日：2012-01-04

    申请人： Angel Janevski ,  Sitharthan Kamalakaran ,  Christian Reichelt ,  Nilanjana Banerjee ,  Vinay Varadan ,  Nevenka Dimitrova

    发明人： Angel Janevski ,  Sitharthan Kamalakaran ,  Christian Reichelt ,  Nilanjana Banerjee ,  Vinay Varadan ,  Nevenka Dimitrova

    IPC分类号： G06F19/00

    CPC分类号： G16H50/70 ,  G06F19/325 ,  G16H40/63

    摘要： A state machine (22) stores a current state (30) comprising a clinical context defined by available patient-related information relating to a medical patient, and identifies one or more available analytical tools of a set of analytical tools (24) that are applicable to the current state. A graphical user interface module (16) receives a user selection of an available analytical tool. The state machine loads patient-related information (40) to the user-selected available analytical tool (24sel) and invokes the user-selected available analytical tool to operate on the loaded patient-related information to generate additional patient-related information relating to the medical patient and/or graphical patient-related content relating to the medical patient. The state machine transitions from the current state (30) to a next state (30′) and/or invokes the graphical user interface module to display the graphical patient related content.

    摘要翻译： 状态机（22）存储当前状态（30），其包括由与医疗患者有关的可用患者相关信息定义的临床上下文，并且识别可应用的一组分析工具（24）中的一个或多个可用分析工具 到目前状态。 图形用户界面模块（16）接收可用分析工具的用户选择。 状态机将患者相关信息（40）加载到用户选择的可用分析工具（24sel），并且调用用户选择的可用分析工具对所加载的患者相关信息进行操作，以生成与患者相关的附加信息 与患者有关的医疗病人和/或图形患者相关内容。 状态机从当前状态（30）转换到下一状态（30'）和/或调用图形用户界面模块以显示图形的患者相关内容。

    Computational Analysis of the Synergy Among Multiple Interacting Factors
    9.
    发明申请
    Computational Analysis of the Synergy Among Multiple Interacting Factors 审中-公开
    多重交互因子之间协同作用的计算分析

    公开(公告)号：US20120290218A1

    公开(公告)日：2012-11-15

    申请号：US13534578

    申请日：2012-06-27

    申请人： Dimitris Anastassiou ,  Vinay Varadan

    发明人： Dimitris Anastassiou ,  Vinay Varadan

    IPC分类号： G06F19/22 ,  G06F15/00

    CPC分类号： C12Q1/6883 ,  C12Q2600/158

    摘要： A method is provided for selecting two or more genes from gene expression data. In the method, gene expression data for a plurality of genes is provided, where the gene expression data include expression levels for each of the plurality of genes. The gene expression data is discretized. Based on the discretized gene expression data, the synergy among the plurality of genes with respect to a phenotype, for example, presence or absence of a disease in a tissue, is evaluated. Two or more genes whose synergy exceeds a predetermined threshold are selected. A system implementing the method is also provided.

    摘要翻译： 提供从基因表达数据中选择两个或多个基因的方法。 在该方法中，提供了多个基因的基因表达数据，其中基因表达数据包括多个基因中的每一个的表达水平。 基因表达数据离散化。 基于离散化的基因表达数据，评估了多个基因相对于表型的协同作用，例如组织中存在或不存在疾病。 选择两个或更多个协同作用超过预定阈值的基因。 还提供了一种实现该方法的系统。

    COMPOSITIONS AND METHODS FOR MICRO-RNA EXPRESSION PROFILING OF COLORECTAL CANCER
    10.
    发明申请
    COMPOSITIONS AND METHODS FOR MICRO-RNA EXPRESSION PROFILING OF COLORECTAL CANCER 有权
    组合物和方法用于微小RNA表达色谱分析

    公开(公告)号：US20110281756A1

    公开(公告)日：2011-11-17

    申请号：US13129289

    申请日：2009-11-13

    申请人： Ying Wu ,  Hongguang Zhu ,  Jian Li ,  Liang Xu ,  Wilhelmus F.J. Verhaegh ,  Yiping Ren ,  Angel Janevski ,  Vinay Varadan ,  Zhaoyong Li ,  Nevenka Dimitrova

    发明人： Ying Wu ,  Hongguang Zhu ,  Jian Li ,  Liang Xu ,  Wilhelmus F.J. Verhaegh ,  Yiping Ren ,  Angel Janevski ,  Vinay Varadan ,  Zhaoyong Li ,  Nevenka Dimitrova

    IPC分类号： C40B30/04 ,  C07H21/02 ,  C12Q1/68

    CPC分类号： C12N15/111 ,  C12N2310/141 ,  C12N2320/10 ,  C12N2330/10 ,  C12N2330/31 ,  C12Q1/6816 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/178

    摘要： The present invention relates compositions and methods for microRNA (miRNA) expression profiling of colorectal cancer. In particular, the invention relates to a diagnostic kit of molecular markers for identifying one or more mammalian target cells exhibiting or having a predisposition to develop colorectal cancer, the kit comprising a plurality of nucleic acid molecules, each nucleic acid molecule encoding a miRNA sequence, wherein one or more of the plurality of nucleic acid molecules are differentially expressed in the target cells and in one or more control cells, and wherein the one or more differentially expressed nucleic acid molecules together represent a nucleic acid expression signature that is indicative for the presence of or the predisposition to develop colorectal cancer. The invention further relates to corresponding methods using such nucleic acid expression signatures for identifying one or more mammalian target cells exhibiting or having a predisposition to develop colorectal cancer as well as for preventing or treating such a condition. Finally, the invention is directed to a pharmaceutical composition for the prevention and/or treatment of colorectal cancer.

    摘要翻译： 本发明涉及用于结肠直肠癌的微小RNA（miRNA）表达谱的组合物和方法。 特别地，本发明涉及用于鉴定表现出或具有发生结肠直肠癌倾向的一种或多种哺乳动物靶细胞的分子标记用诊断试剂盒，所述试剂盒包含多个核酸分子，编码miRNA序列的每个核酸分子， 其中所述多个核酸分子中的一个或多个在靶细胞和一个或多个对照细胞中差异表达，并且其中所述一个或多个差异表达的核酸分子一起表示指示存在的核酸表达特征 或发生结肠直肠癌的倾向。 本发明还涉及使用这种核酸表达特征鉴定一种或多种表现出或具有发生结肠直肠癌倾向的哺乳动物靶细胞以及预防或治疗这种病症的相应方法。 最后，本发明涉及用于预防和/或治疗结肠直肠癌的药物组合物。